Skip to main content
. Author manuscript; available in PMC: 2021 Aug 3.
Published in final edited form as: Chemistry. 2020 Jul 8;26(43):9459–9465. doi: 10.1002/chem.202000615

Figure 4.

Figure 4.

(a) Endogenous Hsp90 was immunopreciptated from HEK293 cells treated with the indicated amounts of B-Raf peptides. Hsp90 binding to B-raf was evaluated by immunoblotting. (b) Binding of Hsp90 and Cdk4 was evaluated by immunoblotting after treatment with the indicated concentrations of Cdk4-01 and Cdk4-02 and immunoprecipitation of endogenous Hsp90. (c) Binding of Hsp90 and c-Src was evaluated by immunoblotting after treatment with the indicated concentrations of c-Src-01 and c-Src-02 and immunoprecipitation of endogenous Hsp90. (d) HEK293 cells were treated with the indicated amounts of GR-01 or GR-02 then examined for total GR protein by immunoblotting. (e) Representative microscopy images of drug uptake in HEK293 cells treated with 10μM FAM-labeled peptides for 24h. Scale bar = 100μm. NT = non-treated (f) Apoptosis in cancer cells was evaluated by immunoblotting for the apoptotic marker cleaved caspase-3 in 786-O cells treated with the kinase peptide mimics. (g) Apoptosis in cancer cells was evaluated by immunoblotting for the apoptotic marker cleaved caspase-3 in 786-O cells treated with the kinase peptide mimics.